全文获取类型
收费全文 | 84篇 |
免费 | 57篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 17篇 |
妇产科学 | 1篇 |
基础医学 | 1篇 |
临床医学 | 14篇 |
内科学 | 29篇 |
皮肤病学 | 5篇 |
神经病学 | 9篇 |
外科学 | 15篇 |
预防医学 | 7篇 |
肿瘤学 | 36篇 |
出版年
2024年 | 1篇 |
2023年 | 7篇 |
2022年 | 1篇 |
2021年 | 7篇 |
2020年 | 10篇 |
2019年 | 6篇 |
2018年 | 15篇 |
2017年 | 11篇 |
2016年 | 16篇 |
2015年 | 12篇 |
2014年 | 17篇 |
2013年 | 7篇 |
2012年 | 6篇 |
2010年 | 13篇 |
2009年 | 4篇 |
2008年 | 2篇 |
2007年 | 2篇 |
2006年 | 1篇 |
2005年 | 1篇 |
2003年 | 2篇 |
排序方式: 共有141条查询结果,搜索用时 15 毫秒
91.
Manik Chhabra PharmD Mohamed Ben-Eltriki PhD MSc BSPS RPh Arun Paul PharmD Mê-Linh Lê MA MLIS Anthony Herbert MBBS BMedSci Sapna Oberoi DM MD Natalie Bradford PhD MPH BNur Alison Bowers PhD MClinRes BN S. Rod Rassekh MD MHSc Lauren E. Kelly PhD MSc BMedSci CCRP 《Cancer》2023,129(22):3656-3670
Background
Despite the widespread use of medical cannabis, little is known regarding the safety, efficacy, and dosing of cannabis products in children with cancer. The objective of this study was to systematically appraise the existing published literature for the use of cannabis products in children with cancer.Methods
This systematic review, registered with the International Prospective Register of Systematic Reviews (CRD42020187433), searched four databases: MEDLINE, Embase, PsycINFO, and the Cochrane Library. Abstracts and full texts were screened in duplicate. Data on types of cannabis products, doses, formulations, frequencies, routes of administration, indications, and clinical and demographic details as well as reported efficacy outcomes were extracted. Data on cannabinoid-related adverse events were also summarized.Results
Out of 34,611 identified citations, 19 unique studies with a total of 1927 participants with cancer were included: eight retrospective chart reviews, seven randomized controlled trials, two open-label studies, and two case reports. The included studies reported the use of various cannabis products for the management of symptoms. Cannabinoids were commonly used for the management of chemotherapy-induced nausea and vomiting (11 of 19 [58%]). In controlled studies, somnolence, dizziness, dry mouth, and withdrawal due to adverse events were more commonly associated with the use of cannabinoids. Across all included studies, no serious cannabis-related adverse events were reported.Conclusions
Although there is evidence to support the use of cannabis for symptom management, in children with cancer, there is a lack of rigorous evidence to inform the dosing, safety, and efficacy of cannabinoids. Because of the increasing interest in using cannabis, there is an urgent need for more research on medical cannabis in children with cancer. 相似文献92.
93.
94.
95.
Johanna Hamel MD Phil Lee PhD Melanie D. Glenn MD Tekalign Burka MD In-Young Choi PhD Seth D. Friedman PhD Dennis W. W. Shaw MD Ayla McCalley BA Laura Herbelin CCRP Mazen M. Dimachkie MD Richard Lemmers PhD Silvère M. van der Maarel PhD Richard J. Barohn MD Rabi Tawil MD Jeffrey M. Statland MD 《Muscle & nerve》2020,61(5):644-649
96.
97.
98.
James P. Stevenson MD Corey J. Langer MD Robert A. Somer MD Tracey L. Evans MD Kumar Rajagopalan MD Kimberly Krieger CCRP Mona Jacobs‐Small CCRC Nikolas Dyanick Barry Milcarek PhD Susan Coakley CCRP Suzanne Walker CRNP Beth Eaby‐Sandy CRNP Alexandre Hageboutros MD 《Cancer》2012,118(22):5580-5587
BACKGROUND:
The authors performed a phase 2 study of bevacizumab plus pemetrexed and carboplatin followed by maintenance bevacizumab in patients with advanced, nonsquamous nonsmall cell lung cancer.METHODS:
Previously untreated patients with advanced, nonsquamous nonsmall cell lung cancer and an Eastern Cooperative Oncology Group performance status of 0 or 1 received bevacizumab 15 mg/kg, pemetrexed 500 mg/m2 and carboplatin at an area under the concentration‐time curve of 6 intravenously on day 1 every 21 days. Responding or stable patients who completed 6 cycles then received bevacizumab maintenance every 21 days until disease progression.RESULTS:
In total, 43 patients (40 who were evaluable for response) were entered on the study. Treatment‐related grade 3/4 toxicities were low and included febrile neutropenia (2%), neutropenia (28%), anemia (18%), thrombocytopenia (11%), hypertension (7%), epistaxis (5%), venous thrombosis (8%), dyspnea (7%), rectovaginal fistula (2.3%), infusion reaction (2%), and cerebrovascular event (2%). One patient died from complications of venous thromboembolism and cerebrovascular accident after Cycle 2. Minimal clinically significant toxicity occurred during maintenance bevacizumab. Two complete responses (5%) were observed, and 17 patients (42%) had a partial response. Fifteen patients (38%) displayed disease stability. The overall disease control rate was 85%. At a median follow‐up of 15.8 months, the median progression‐free survival was 7.1 months (95% confidence interval, 5.9‐8.3 months), and the median overall survival was 17.1 months (95% confidence interval, 8.8‐25.5 months).CONCLUSIONS:
Combined bevacizumab, pemetrexed, and carboplatin followed by maintenance bevacizumab was well tolerated and displayed remarkable activity in patients with previously untreated, advanced, nonsquamous nonsmall cell lung cancer. Cancer 2012. © 2012 American Cancer Society. 相似文献99.
Jessie Huisinga PhD Adam Bruetsch MS Ayla Mccalley BS Melissa Currence PTA Laura Herbelin CCRP Omar Jawdat MD Mamatha Pasnoor MD Mazen Dimachkie MD Richard Barohn MD Jeffrey Statland MD 《Muscle & nerve》2018,57(3):503-506
Introduction: Instrumenting timed functional motor tasks may reveal a continuum of motor disability that predicts future motor dysfunction. Methods: We performed a prospective study of the instrumented timed up and go (iTUG) test in genetically confirmed facioscapulohumeral muscular dystrophy (FSHD) participants using a commercially available system of wireless motion sensors. Patients returned within 2 weeks to determine test–retest reliability. Gait parameters in FSHD participants were compared with a normative database, FSHD clinical severity score, manual muscle testing, and patient‐reported functional disability. Results: Gait parameters in FSHD participants were significantly (P < 0.05) altered compared with normative values, and reliability was excellent (intraclass correlation coefficient 0.84–0.99). Stride velocity and trunk sagittal range of motion had moderate to strong correlations to other FSHD disease measures. Discussion: The iTUG was reliable, abnormal in FSHD, and could distinguish between participants with differing disease severities. Instrumenting timed functional tasks may prove to be useful in FSHD clinical trials. Muscle Nerve 57 : 503–506, 2018 相似文献
100.
Daniel K. Nishijima MD MAS Amber L. Laurie MS Robert E. Weiss PhD Annick N. Yagapen MPH CCRP Susan E. Malveau MSBME David H. Adler MD MPH Aveh Bastani MD FACEP Christopher W. Baugh MD MBA Jeffrey M. Caterino MD MPH FACEP Carol L. Clark MD MBA FACEP Deborah B. Diercks MD MSc Judd E. Hollander MD Bret A. Nicks MD MHA Manish N. Shah MD MPH Kirk A. Stiffler MD MPH Alan B. Storrow MD Scott T. Wilber MD MPH Benjamin C. Sun MD MPP 《Academic emergency medicine》2016,23(9):1014-1021